

SUBCUTANEOUS INJECTABLE CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR ANTAGONISTS

AJOVY (fremanezumab)
EMGALITY (galcanezumab)

POLICY

I. CRITERIA FOR APPROVAL

A. Preventative Treatment of Chronic Migraine

An authorization may be granted for the preventative treatment of chronic migraine when all of the following criteria are met:

- A. Member is 18 years of age or older
- B. Medication is prescribed by, or in consultation with a neurologist or headache specialist
- C. Member is experiencing at least 15 headache days per month (tension-type-like and/or migraine-like) days per month for at least 3 months
- D. Member has been fully equipped with abortive migraine therapy, if appropriate, and has had inadequate relief
- E. Member has documented trial and failure of a 3-month trial of any 2 prophylactic medications from the following therapeutic classes:
 - i. Antidepressants (e.g., amitriptyline, venlafaxine)
 - ii. Beta blockers (e.g., propranolol, metoprolol, timolol, atenolol)
 - iii. Anti-epileptics (e.g., valproate, topiramate)
- F. Member has documented trial and failure to a minimum of 2 quarterly injections (6 months) of botulinum toxin (e.g., onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, rimabotulinumtoxinB)
- G. Member is not using medication in combination with other injectable CGRP antagonists (e.g., Ajovy, Emgality, Vyepti) or oral CGRP antagonists (e.g., Ubrelvy, Nurtec ODT), unless oral Nurtec ODT or Ubrelvy is being used for the acute treatment of migraine rather than prevention

B. Preventative Treatment of Episodic Migraine for Pediatrics (Ajovy ONLY)

An authorization may be granted for the preventative treatment of episodic migraine when all of the following criteria are met:

- A. The member is 6 to 17 years of age
- B. The member weighs 45kg or more
- C. Medication is prescribed by, or in consultation with a neurologist or headache specialist
- D. Member is not using medication in combination with other injectable CGRP antagonists (e.g., Ajovy, Emgality, Vyepti) or oral CGRP antagonists (e.g., Ubrelvy, Nurtec ODT), unless oral Nurtec ODT or Ubrelvy is being used for the acute treatment of migraine rather than prevention

II. CONTINUATION OF THERAPY

A. Preventative Treatment of Chronic Migraine

An authorization may be granted for preventative treatment of chronic migraine when all of the following criteria are met:

- A. If member has not been approved for this drug by Neighborhood in the past, clinician must submit documentation that initial criteria is met.
- B. Member is not using medication in combination with other CGRP antagonists (e.g., Ajovy, Emgality, Vyepti, Ubrelvy) for migraine prevention
- C. Member is not using medication in combination with a botulinum toxin unless the member had a clinically significant response to therapy after 2 quarterly injections of botulinum toxin alone
- D. Member has experienced a positive clinical response to therapy as demonstrated by a reduction in headache frequency, duration and/or severity from baseline
 - i. If member is using medication in combination with a botulinum toxin, the member has shown a clinically meaningful incremental benefit from using both products.

B. Preventative Treatment of Episodic Migraine for Pediatrics (Ajovy ONLY)

An authorization may be granted for the preventative treatment of episodic migraine when all of the following criteria are met:

- A. If member has not been approved for this drug by Neighborhood in the past, clinician must submit documentation that initial criteria is met.
- B. Member has experienced a positive clinical response to therapy as demonstrated by a reduction in headache frequency, duration and/or severity from baseline

III. QUANTITY LIMIT

- Ajovy 225mg/1.5ml: 1 injection per month
- Emgality 120mg/ml: 1 injection per month, with post-limit for loading dose of 2 injections (2 ml) for first month

IV. COVERAGE DURATION

- Initial: 6 months
- Continuation: 12 months

V. REFERENCES

1. Ajovy [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; August 2025. Accessed May 2026.
2. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; October 2025. Accessed May 2026.